Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Blood

Volumn 121, Issue 2, 2013, Pages 378-384

  Horn, Matthias ^a   Glauche, Ingmar ^b   Müller, Martin C ^c   Hehlmann, Rüdiger ^c   Hochhaus, Andreas ^d   Loeffler, Markus ^a   Roeder, Ingo ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Universit tsklinikum Jena   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84872334998     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-441956     Document Type: Article

References (33)

1. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370(9584):342- 350.
2. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441-453. (Pubitemid 46823444)
3. Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med. 2002; 346(9):683-693. (Pubitemid 34815874)
4. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270.
5. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24): 2251-2259.
6. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56(1):100-104.
7. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-566.
8. Oetzel C, Jonuleit T, Gotz A, et al. The tyrosine kinase inhibitor CGP 57148 (STI 571) induces apoptosis in BCR-ABL-positive cells by downregulating BCL-X. Clin Cancer Res. 2000;6(5): 1958-1968. (Pubitemid 30305095)
9. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukaemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7(2):228-234. (Pubitemid 32148491)
10. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukemia. Nature. 2005; 435(7046):1267-1270.
11. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med. 2006;12(10):1181-1184. (Pubitemid 44527354)
12. Wilson A, Laurenti E, Oser G, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135(6):1118-1129.
13. Glauche I, Moore K, Thielecke L, Horn K, Loeffler M, Roeder I. Stem cell proliferation and quiescence: two sides of the same coin. PLoS Comput Biol. 2009;5(7):e1000447.
14. Hochhaus A, O'Brien SG, Guilhot F, et al. Sixyear follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054-1161.
15. Hochhaus A. Minimal residual disease in chronic myeloid leukaemia patients. Best Pract Res Clin Haematol. 2002;15(1):159-178. (Pubitemid 34285189)
16. Goldman J. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol. 2005;12(1): 33-39. (Pubitemid 40189237)
17. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24(10):1719- 1724.
18. Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
19. Roeder I, Loeffler M. A novel dynamic model of hematopoietic stem cell organization based on the concept of within-tissue plasticity. Exp Hematol. 2002;30(8):853-861. (Pubitemid 34851245)
20. Horn M, Loeffler M, Roeder I. Mathematical modeling of genesis and treatment of chronic myeloid leukemia. Cells Tissues Organs. 2008;188(1-2): 236-247. (Pubitemid 351962246)
21. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011;29(12):1634-1642.
22. Davies RB. Hypothesis testing when a nuisance parameter is present only under the alternative. Biometrika. 1987;74(1):33-43.
23. Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172-2175.
24. Sloma I, Jiang X, Eaves AC, Eaves CJ. Insights into the stem cells of chronic myeloid leukemia. Leukemia. 2010;24(11):1823-1833.
25. Graham SM, Jørgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1): 319-325.
26. Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol. 2010;4(5):443-450.
27. Tang M, Gonen M, Quintas-Cardama A, et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 2011; 118(6):1622-1631.
28. Stein AM, Bottino D, Modur V, et al. BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clin Cancer Res. 2011;17(21):6812- 6821.
29. Tauchi T, Ohyashiki K. Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk Res. 2004;28(Suppl 1):S39-S45. (Pubitemid 38251497)
30. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major BCR-ABL gene expression at a very low level in blood cells of some healthy individuals. Blood. 1995;86(8):3118-3122.
31. Foo J, Drummond MW, Clarkson B, Holyoake T, Michor F. Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol. 2009;5(9):e1000503.
32. Tang M, Foo J, Gonen M, Guilhot J, Mahon FX, Michor F. Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. Haematologica. 2012; 97(10):1553-1561.
33. Sawyers CL. Even better kinase inhibitors for chronic myeloid leukemia. N Engl J Med. 2010;362(24): 2314-2315.